CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
NEW YORK, July 17, 2017 -- Ember Therapeutics, Inc. (OTCQB:EMBT), a diversified New York-based pharmaceutical company developing targeted therapies for osteoarthritis, fibrosis, and other regenerative medicines, today announced that scientists have validated a molecular mechanism that regulates scar formation in the heart, a common manifestation of aging and nearly every form of heart disease. Additionally, scientist confirmed that a protein called bone morphogenetic protein 7 (BMP-7) can prevent the generation of fibrotic signals by cardiomyocytes and may be able to serve as a therapy for cardiac fibrosis. The data was published in the journal Circulation.
Tissue fibrosis is the leading cause of organ failure. There is a lack of effective therapies. Currently, the only cure for cardiac fibrosis is heart transplantation.
“This work validates that the use of BMP-7 as a unique therapeutic strategy to prevent cardiac fibrosis,” said Joseph Hernandez, Ember’s Executive Chairman. “Ember has an extensive patent portfolio of over 400 patents in the use of BMP-7 in fibrosis and other indications. We are delighted with this data and look forward to partnering our intellectual property in this area of severe clinical need,” added Mr. Hernandez.
About Ember Therapeutics, Inc.
Ember Therapeutics, Inc. is a diversified pharmaceutical company commercializing and developing targeted therapies for pain, osteoarthritis, fibrosis and other regenerative medicines. In particular, Ember Therapeutics, Inc. has several commercial products and two late stage Phase 3 ready assets. For more information, please visit www.embertx.com
Ember Therapeutics Forward-Looking Statements
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Ember Therapeutics’ business and Ember Therapeutics undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Contact Information: Betty Rose (investors) [email protected]
